IRCT138903013862N2 IRCT 2010-06-08 Research Council of Mashhad University of Medical Sciences Study of efficacy and side effects of Pioglitazone in the treatment of psoriasis Study of efficacy and side effects of Pioglitazone in the treatment of plaque psoriasis vulgaris 2007-09-26 anticipated 26 Complete https://irct.ir/trial/3999 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2-3 Psoriasis. oral Pioglitazone 30 mg daily for 12 weeks.

public Hadis Yousefzadeh

Research center of skin diseases and leishmaniasis, Office building, Ghaem Hospital, Ahmad Abad Street

Mashhad Iran (Islamic Republic of) +98 51 1732 7027 hadis_yousefzadeh@yaoo.com Research center for skin disease and cutaneous leishmaniasis scientific Dr Pouran Layegh

Department of Dermatology, Qaem Hospital, Mashad University of Medical Sciences

Mashhad Iran (Islamic Republic of) +98 51 1881 4988 layeghpo@mums.ac.ir Mashad University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: new cases of plaque psoriasis which don’t received systematic treatment during last 3 months and for topical treatment last month, patients complete consent form and participate to study consciously. Exclusion criteria: patients who want to leave study deliberately, sensitive to pioglitazone or the same preparations, type one diabetes mellitus, pregnant or lactating women, below 18 years old, with severe hepatic problems (hepatitis, alcoholic or non alcoholic steatohepatitis, cirrhosis), severe cardiovascular disorders (NYHA CLASS III & IV), patients prevent pregnancy only by oral contraceptives, patients that have any of these following side effects during therapy: upper respiratory tract infections and sinusitis, edema and any indicative sign of heart failure, unwanted pregnancy, weight gain, anemia, leuckopenia, hematuria, jaundice and 3 times increment of hepatic enzymes (ALT), any symptom which make patients to leave the study. Patients who used any of these drugs (Oral contraceptives, Gatifloxacin ,Insulin ,sulfunamides ,sulfunylureas, Thioridazine , Gemfibrozil). 18 years 80 years Both L40.0 Psoriasis vulgaris Treatment - Drugs oral Pioglitazone 30 mg daily for 12 weeks Psoriasis severity. Timepoint: monthly untill the end of 12 weeks. Method of measurement: PASI standard method. Side effect. Timepoint: monthly untill end of 12 weeks. Method of measurement: Standard evaluation method for this disease. Research Council of Mashhad University of Medical Sciences Approved 2007-10-26 Ethics Committee of Mashad University of Medical Sciences Central Building of Mashad University of Medical Sciences, Mashad, Iran Mashhad Iran (Islamic Republic of)